Dako owner will make Danish pathology company a global player
![Michael Grunkin, CEO of Visiopharm, is happy about the new partnership. | Foto: Visiopharm / PR](https://photos.watchmedier.dk/watchmedier/resize:fill:3840:0:0/plain/https://photos.watchmedier.dk/Images/article11987675.ece/ALTERNATES/schema-16_9/doc79k41ihujup18h2oumh3.jpg)
One company is Danish and had an DKK 88 million (USD 13.1 million) revenue in 2018/2019. The other is based in the US, and boasted DKK 35 billion (USD 5.2 billion) on its topline for the same year.
Læs hele artiklen
Få adgang i 14 dage for 0 kr. Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.